Genmab — Marts 2025
-
Ja mener ikke det har oget med have patent at gøre. Jeg har selv underskrevet ansættelseskontrakter hvor der stod at viden opnået igennem arbejdet tilhører virksomheden (intellektual property). Fet handler som jeg ser det om gl medarbejdere fra Abbv som skulle have brugt viden som Abbv anser som deres intellektuelle ejendom
-
Der er et utal af juridiske slagsmål og retstvister om stort og småt indenfor pharma, biotek og medico. Antallet af sager er eskaleret eksplosivt siden 1990´erne.
-
De må jo gære noget så ikke deres $10bn køb i 2023 ikke ser helt håbløs ud https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio For mig at se er det et kæmpe problem for Elahere, at der er “ Fatal adverse reactions occurred in 2% of patients” https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtan
-
Genmabs langsigtede salgsprognoser https://proinvestor.com/boards/125146
-
Godmorgen
-
Genmab sagsøges for misbrug af forretningshemmeligheder https://proinvestor.com/investornyt/1294524/genmab-sagsoges-for-misbrug-af-forretningshemmeligheder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind